Remdesivir News and Research

RSS

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.

2 Dec 2021

An antiviral regimen based on biomimetic polymers for COVID-19

In a new study published on the bioRxiv* preprint server, scientists proposed the aforementioned mechanism of action (MOA) and have validated it using electron photomicrographs of murine cytomegalovirus (MCMV), which were incubated with a nanoviricide.

30 Nov 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.

29 Nov 2021

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

To the untrained eye, the loops, kinks and folds in the single strand of RNA that makes up the coronavirus genome look like a jumble of spaghetti or tangled yarn. But to researchers like Amanda Hargrove, a chemistry professor at Duke University, the complex shapes that RNA takes on as it folds upon itself could have untapped therapeutic potential in the fight against COVID-19.

26 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

An increase in the half-life of remdesivir for COVID-19 treatment

In this study, researchers analyzed several drug candidates to investigate their efficacy against a broad spectrum of coronaviruses in cell culture studies.

23 Nov 2021

IFITM proteins are important replication cofactors for SARS-CoV-2, including Delta variant

In a study recently published on the bioRxiv* preprint server, researchers investigated the IFITM2 dependency of SARS-CoV-2 VOCs, including the delta variant for efficient infection.

22 Nov 2021

Modeling the role of antivirals in suppressing the COVID-19 pandemic

A new study used an agent-based mathematical model to evaluate potential population impact on the widespread use of antiviral treatment for reducing viral load and hospitalization risk.

16 Nov 2021

Could drugs derived from microalgae be effective against COVID-19?

Researchers discuss the ability of some microalgae metabolites to prevent cytokine storm syndrome during COVID-19.

15 Nov 2021

Xanthohumol as a potent pan-inhibitor for various coronaviruses

Researchers from China reported the results of their study aimed at finding an effective Mpro inhibitor since Mpro is the best drug target to fight SARS-CoV-2 infection.

12 Nov 2021

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

A research group from the US (led by experts from Yale University School of Medicine) recently presented a case of an immunocompromised female patient with acquired deficiency of B lymphocytes who subsequently developed a protracted course of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2021

Emergence of SARS-CoV-2 immune escape variants in an immunocompromised patient

A German case study recently published in the journal Nature Communications has characterized a long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dynamics in an immunosuppressed kidney transplant recipient and provided evidence for the evolution of SARS-CoV-2 into potentially harmful immune escape mutants during persistent infections.

10 Nov 2021